AC Immune shares surged over 23% after the company reported positive interim Phase 2 results for its Parkinson treatment ACI-7104.056. The study showed a 100% responder rate and suggested, for the first time, that active immunotherapy targeting a-syn pathology may slow disease progression. The company plans to seek regulatory feedback to accelerate development.